We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Neogen (NEOG) Down 3.6% Since Last Earnings Report: Can It Rebound?
Read MoreHide Full Article
It has been about a month since the last earnings report for Neogen (NEOG - Free Report) . Shares have lost about 3.6% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Neogen due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
Neogen's Q3 Earnings Miss Estimates, Gross Margin Expands
Neogen reported third-quarter fiscal 2024 earnings per share of 12 cents, unchanged from the prior year’s comparable period figure. The reported figure missed the Zacks Consensus Estimate by 14.3%.
Revenues in the fiscal third quarter rose 4.8% on a year-over-year basis to $228.8 million. Core revenues were 6.2%. Acquisitions and discontinued product lines did not impact core growth, while foreign currency posed a negative impact of 1.4%. The metric missed the Zacks Consensus Estimate by 0.5%.
Segments in Detail
Within segments, Neogen registered Food Safety revenues of $157.8 million in the fiscal third quarter, marking a 4.1% improvement from the prior-year period, led by 5.8% core growth and 0.2% growth from acquisitions and discontinued product lines, offset by a negative foreign currency impact of 1.9%.
The core revenue growth in the segment was led by Indicator Testing, Culture Media & Other product category, which benefited from higher sales of Petrifilm, as well as sample handling and nutritional analysis products. However, this was partially offset by a decline in culture media sales, primarily due to a larger, one-time order in the prior-year period.
Revenues from Animal Safety were $71.1 million, up 6.5% year over year. The upside was caused by a core revenue growth of 7%, a 0.2% headwind from discontinued product lines and a negative foreign currency impact of 0.3%.
The core growth in the segment was led by Neogen’s portfolio of biosecurity products, driven by new business wins and increased demand for cleaners, disinfectants and insect control products.
On a global basis, Neogen’s Genomics business witnessed a core revenue decline in the mid-single-digit range, with increased sales in international beef markets offset by customer attrition in the United States, a result of the aforementioned strategic shift in focus.
Margin Details
Neogen’s fiscal third-quarter gross profit increased 8.3% year over year to $116.9 million. The gross margin expanded 162 basis points (bps) to 51.1%. The upside was led by a favorable impact from the product mix.
Sales and marketing expenses rose 30.9% to $47.9 million, whereas administrative expenses increased 12.2% from the prior-year quarter to $52 million.
R&D expenses were $4.9 million, down 33.1% year over year. Operating costs totaled $104.9 million, up 16.2% from the year-ago quarter.
The company reported an operating profit of $12 million for the fiscal third quarter compared with $15.7 million in the year-ago quarter.
Cash Position
Neogen exited the third quarter of fiscal 2024 with cash and investments of $161.4 million compared with $205.8 million at the fiscal second quarter of 2024-end. At the fiscal third-quarter end, the company’s non-current liabilities included a total outstanding debt of $900 million and committed borrowing headroom of $150 million.
Full-Year Guidance
Neogen updated its outlook for fiscal 2024.
The company anticipates full-year revenues in the band of $910 million-$920 million (down from the previous guidance of $935-$955 million). The Zacks Consensus Estimate for the same is currently pegged at $938.1 million.
NEOG expects capital expenditures to be approximately $130 million, which includes approximately $100 million related specifically to the integration of the former 3M Food Safety Division (unchanged).
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in fresh estimates.
The consensus estimate has shifted -34.29% due to these changes.
VGM Scores
At this time, Neogen has a poor Growth Score of F, a grade with the same score on the momentum front. Charting a somewhat similar path, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise Neogen has a Zacks Rank #4 (Sell). We expect a below average return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Neogen (NEOG) Down 3.6% Since Last Earnings Report: Can It Rebound?
It has been about a month since the last earnings report for Neogen (NEOG - Free Report) . Shares have lost about 3.6% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Neogen due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
Neogen's Q3 Earnings Miss Estimates, Gross Margin Expands
Neogen reported third-quarter fiscal 2024 earnings per share of 12 cents, unchanged from the prior year’s comparable period figure. The reported figure missed the Zacks Consensus Estimate by 14.3%.
Revenues in the fiscal third quarter rose 4.8% on a year-over-year basis to $228.8 million. Core revenues were 6.2%. Acquisitions and discontinued product lines did not impact core growth, while foreign currency posed a negative impact of 1.4%. The metric missed the Zacks Consensus Estimate by 0.5%.
Segments in Detail
Within segments, Neogen registered Food Safety revenues of $157.8 million in the fiscal third quarter, marking a 4.1% improvement from the prior-year period, led by 5.8% core growth and 0.2% growth from acquisitions and discontinued product lines, offset by a negative foreign currency impact of 1.9%.
The core revenue growth in the segment was led by Indicator Testing, Culture Media & Other product category, which benefited from higher sales of Petrifilm, as well as sample handling and nutritional analysis products. However, this was partially offset by a decline in culture media sales, primarily due to a larger, one-time order in the prior-year period.
Revenues from Animal Safety were $71.1 million, up 6.5% year over year. The upside was caused by a core revenue growth of 7%, a 0.2% headwind from discontinued product lines and a negative foreign currency impact of 0.3%.
The core growth in the segment was led by Neogen’s portfolio of biosecurity products, driven by new business wins and increased demand for cleaners, disinfectants and insect control products.
On a global basis, Neogen’s Genomics business witnessed a core revenue decline in the mid-single-digit range, with increased sales in international beef markets offset by customer attrition in the United States, a result of the aforementioned strategic shift in focus.
Margin Details
Neogen’s fiscal third-quarter gross profit increased 8.3% year over year to $116.9 million. The gross margin expanded 162 basis points (bps) to 51.1%. The upside was led by a favorable impact from the product mix.
Sales and marketing expenses rose 30.9% to $47.9 million, whereas administrative expenses increased 12.2% from the prior-year quarter to $52 million.
R&D expenses were $4.9 million, down 33.1% year over year. Operating costs totaled $104.9 million, up 16.2% from the year-ago quarter.
The company reported an operating profit of $12 million for the fiscal third quarter compared with $15.7 million in the year-ago quarter.
Cash Position
Neogen exited the third quarter of fiscal 2024 with cash and investments of $161.4 million compared with $205.8 million at the fiscal second quarter of 2024-end. At the fiscal third-quarter end, the company’s non-current liabilities included a total outstanding debt of $900 million and committed borrowing headroom of $150 million.
Full-Year Guidance
Neogen updated its outlook for fiscal 2024.
The company anticipates full-year revenues in the band of $910 million-$920 million (down from the previous guidance of $935-$955 million). The Zacks Consensus Estimate for the same is currently pegged at $938.1 million.
NEOG expects capital expenditures to be approximately $130 million, which includes approximately $100 million related specifically to the integration of the former 3M Food Safety Division (unchanged).
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in fresh estimates.
The consensus estimate has shifted -34.29% due to these changes.
VGM Scores
At this time, Neogen has a poor Growth Score of F, a grade with the same score on the momentum front. Charting a somewhat similar path, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise Neogen has a Zacks Rank #4 (Sell). We expect a below average return from the stock in the next few months.